Background and Aims: Cisplatin-induced nephrotoxicity primarily occurs in the proximal tubules, and tubular injuries reduce glomerular filtration rates. Lower blood pressure causes renal hypoperfusion, which promotes ischemic acute kidney injury (AKI). Our study examined the relationship between lower blood pressure-induced renal hypoperfusion and cisplatin-induced nephrotoxicity. Methods: The relationship between cisplatin use and hypoalbuminemia is not clear. This study consisted of Japanese patients who received cisplatin as the first-line chemotherapy at Fujita Health University Hospital from April 2006 to December 2012. Hypoalbuminemia was defined as serum albumin levels ≤3.5 mg/dl. Results: Patients who experienced lower blood pressure during chemotherapy were included in the lower blood pressure group (n = 229), and those who did not were included in the normal blood pressure group (n = 743). Total cisplatin dose in the normal blood pressure and lower blood pressure groups was 58.9 ± 23.8 and 55.0 ± 20.4 mg/m2, respectively. The rate of severe nephrotoxicity was higher and overall survival was shorter in the lower blood pressure group than in the normal blood pressure group. In a multivariable analysis, lower blood pressure significantly correlated with hypoalbuminemia. Conclusions: To prevent ischemic AKI, nutrition and cachexia controlling are important parts of cancer treatment.

Keywords:
Lower blood pressure, Cisplatin, Nephrotoxicity, Hypoperfusion
1.
Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-464.
2.
Morrell ED, Kellum JA, Hallows KR, Pastor-Soler NM: Epithelial transport during septic acute kidney injury. Nephrol Dial Transplant 2014;29:1312-1319.
3.
Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC: Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008;61:145-155.
4.
Devarajan P: Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006;17:1503-1520.
5.
Abuelo JG: Normotensive ischemic acute renal failure. N Engl J Med 2007;357:797-805.
6.
Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A: Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35:871-881.
7.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
8.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
9.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
10.
Finley RS, Fortner CL, Grove WR: Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm 1985;19:362-367.
11.
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977;39:1357-1361.
12.
Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A: Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93:138-144.
13.
Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T: Short hydration in chemotherapy containing cisplatin (>/=75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 2013;43:1105-1109.
14.
Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K: Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 2013;43:1115-1123.
15.
Wong BT, Chan MJ, Glassford NJ, Martensson J, Bion V, Chai SY, Oughton C, Tsuji IY, Candal CL, Bellomo R: Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. J Crit Care 2015;30:975-981.
16.
Correa TD, Vuda M, Takala J, Djafarzadeh S, Silva E, Jakob SM: Increasing mean arterial blood pressure in sepsis: effects on fluid balance, vasopressor load and renal function. Crit Care 2013;17:R21.
17.
Dharan KS, John GT, Antonisamy B, Kirubakaran MG, Jacob CK: Prediction of mortality in acute renal failure in the tropics. Ren Fail 2005;27:289-296.
18.
Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E, Noda Y: The risk factors of severe acute kidney injury induced by cisplatin. Oncology 2013;85:364-369.
19.
de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ, Stoter G, Verweij J: Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003;88:1199-1206.
20.
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R: Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-308.
21.
Nanji AA, Stewart DJ, Mikhael NZ: Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 1986;17:274-276.
22.
Nanji AA, Mikhael NZ, Stewart DJ: Hypoalbuminemia in patients receiving cisplatin: correlation between liver platinum and decrease in serum albumin. Oncology 1986;43:33-35.
23.
Santarpia L, Contaldo F, Pasanisi F: Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle 2011;2:27-35.
24.
Murry DJ, Riva L, Poplack DG: Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998;11:48-51.
25.
Reece PA, Stafford I, Russell J, Khan M, Gill PG: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987;5:304-309.
26.
Nagai N, Ogata H: Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 1997;40:11-18.
27.
Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y: Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 1996;39:131-137.
28.
Dalal S, Bruera E: Dehydration in cancer patients: to treat or not to treat. J Support Oncol 2004;2:467-479, 483.
29.
Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, Sekine I, Tada Y, Tatsumi K, Takiguchi Y: Safety of a short hydration method for cisplatin administration in comparison with a conventional method - a retrospective study. Jpn J Clin Oncol 2016;46:370-377.
30.
Yamamoto Y, Watanabe K, Tsukiyama I, Matsushita H, Yabushita H, Matsuura K, Wakatsuki A: Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin. Anticancer Res 2015;35:2199-2204.
31.
Oka T, Kimura T, Suzumura T, Yoshimoto N, Nakai T, Yamamoto N, Matsuura K, Mitsuoka S, Yoshimura N, Kudoh S, Hirata K: Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol 2014;15:70.
32.
Bagshaw SM, George C, Bellomo R: Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11:R68.
33.
Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
34.
Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK: Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev 2009:Cd006028.
35.
Friedrich JO, Adhikari N, Herridge MS, Beyene J: Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-524.
36.
Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D: Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol 2002;13(suppl 3):S224-S229.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.